FDA Approval, Clinical Trial Evidence, Efficacy, Epidemiology, and Price for Non-orphan and Ultra-rare, Rare, and Common Orphan Cancer Drug Indications
Recommended
FDA Approval, Clinical Trial Evidence, Efficacy, Epidemiology, and Price for Non-orphan and Ultra-rare, Rare, and Common Orphan Cancer Drug Indications
In this cross sectional analysis, German investigators aim to refine the US Orphan Drug Act of 1983 by comparing orphan and non-orphan cancer drug indications against factors including FDA approval status, trial evidence, pricing, and unmet needs.
Access the full press release to read more here.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->